NCT07263958Not yet recruiting
Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)
HOLLYWOOD: Hemodynamic Evaluation and Management of Pulmonary Hypertension With Inhaled Iloprost in Chronic Obstructive Pulmonary Disease
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
Study Title: A Clinical Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension in Patients With Chronic Obstructive Pulmonary Disease (HOLLYWOOD) The goal of this clinical study is to learn if the inhaled drug iloprost is effective and safe for treating pulmonary hypertension (PH) in adult patients who have severe or very severe Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: Does inhaled iloprost reduce the pressure and resistance in the lung's blood vessels (measured as Pulmonary Vascular Resistance - PVR)? Does inhaled iloprost improve participants' ability to exercise, measured by how far they can walk in 6 minutes? What are the side effects and medical problems that participants experience while taking inhaled iloprost? Researchers will assess changes in participants' health by comparing measurements taken before they start taking inhaled iloprost to measurements taken after 12 weeks of treatment. There is no placebo group in this study. Participants in this study will: Use an inhaler to take iloprost 6 to 9 times every day for 12 weeks. Visit the clinic for checkups at the beginning of the study and after the 12-week treatment period. Undergo tests including an exercise capacity test (the 6-minute walk test) and heart pressure measurements (hemodynamic tests) before and after the treatment period.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 5 Sept 2025
- Start date
- 10 Dec 2025
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- University of Sao Paulo General Hospital
- NCT number
- NCT07263958
What you commit to
- Study type: Interventional
- Planned participants: 15
- From 10 Dec 2025 to the primary completion date, 30 Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of hypersensitivity to iloprost or other prostacyclin analogs.
Other
- Pregnancy or breastfeeding.
Who the study is looking for
- Age 40 years or older.
- Established diagnosis of severe or very severe Chronic Obstructive Pulmonary Disease (COPD), corresponding to GOLD stage 3 or 4.
- Symptomatic Group 3 Pulmonary Hypertension (PH) confirmed by Right Heart Catheterization (RHC) with the following hemodynamic profile at rest:
- Mean Pulmonary Artery Pressure (mPAP) \> 35 mmHg.
- Pulmonary Vascular Resistance (PVR) \> 5 Wood Units (WU).
- Pulmonary Capillary Wedge Pressure (PCWP) ≤ 15 mmHg.
- Capable of providing written informed consent.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.